Multicell therapies mimic naturally occurring mixed-cell populations and cellular conjugates. By mimicking native multicells, multicell therapies improve therapeutic half-life by preventing premature clearance in vivo.
Manufacturing challenges often are similar to the single cell challenges. However, the co-cultures and conjugates require additional consideration for expansion.
Theragent’s researchers bring experience across a broad swath of cell culture applications, including NK and T cells.
Multicells have a wide variety of clinical uses in immuno-oncology and autoimmune disorders. Furthermore, the cells chosen for the pairing are complementary in their therapeutic effect. One example pairing that has become prevalent in early-stage development of this technology is the NK/T-cell multicell conjugate. By pairing NK cells and T-cells, the therapeutic engages both the innate immune response using the NK, as well as the adaptive immune response using T cells. Culture and expansion of multicells must be done concurrently with both cell types. Co-culture timing and conditions are dependent on the desired multicell product, includes needs for cell phenotypes, cell ratios, and the cells’ function. Furthermore, the multicell conjugates must have optimized manufacturing conditions to ensure the complex is stable.
Theragent’s researchers bring experience across a broad swath of cell culture applications, including NK and T cells. When you need to optimize the concurrent culture of different cell types, Theragent’s team is ready to work with you to ensure a stable complex.